| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
General Counsel
1 company
Miller Edward is a General Counsel at Kalaris Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 12 sells.
Estimated insider holdings value: $31K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 379 | $0.72 | $272.88 | -0.2% | +10.0% | -84.9% | |
| May 17, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 420 | $0.75 | $314.71 | -0.2% | -5.8% | -80.5% | |
| May 3, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 2,311 | $0.80 | $1,839.56 | -1.0% | +0.3% | -68.2% | |
| Apr 22, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 1,383 | $0.75 | $1,037.63 | -0.3% | -0.6% | -61.5% | |
| Apr 2, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 368 | $0.77 | $284.10 | -0.2% | -4.9% | -54.3% | |
| Feb 20, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 385 | $0.70 | $267.65 | -0.2% | +9.2% | -35.7% | |
| Feb 5, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 8,869 | $0.67 | $5,942.23 | -3.8% | +20.3% | -34.7% | |
| Jan 23, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 1,302 | $0.67 | $873.38 | -0.6% | +13.9% | -40.3% | |
| Jan 4, 2024 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 424 | $0.64 | $270.94 | -0.2% | +14.3% | -32.4% | |
| Jan 20, 2023 | KLRS Kalaris Therapeutics, Inc. | General Counsel | Sell | 2,573 | $5.09 | $13,100.68 | -0.9% | -28.0% | -87.0% |